| Followers | 73 |
| Posts | 3034 |
| Boards Moderated | 0 |
| Alias Born | 06/01/2012 |
Tuesday, November 06, 2012 9:30:29 PM
If they get the NDA for 130 filed before the end 1st qtr of 2013 I'd be surprised. I'm not saying it shouldn't be done as it should have been submitted way before now, but given mgmts track record I believe it speaks for itself.
Recent CSCIF News
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 05/20/2026 08:46:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2026 08:38:12 PM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 05/12/2026 09:21:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/12/2026 09:07:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/12/2026 09:05:51 PM
- COSCIENS Biopharma Inc. Reports Q1 2026 Results • GlobeNewswire Inc. • 05/12/2026 09:05:00 PM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 05/08/2026 08:45:33 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2026 08:45:07 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 04/20/2026 12:01:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/20/2026 12:00:12 PM
- COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations • GlobeNewswire Inc. • 04/20/2026 12:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/17/2026 09:55:15 PM
- COSCIENS Comments on Unusual Market Activity • GlobeNewswire Inc. • 04/07/2026 09:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/07/2026 09:07:44 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/25/2026 09:05:27 PM
- COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/25/2026 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/19/2026 04:15:19 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/13/2026 09:30:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/13/2026 09:30:39 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/13/2026 09:30:14 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/13/2026 09:29:54 PM
